Multilevel models for survival analysis with random effects. Long-term beta-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Korean National Health Insurance Database. Cohort profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Ezetimibe added to statin therapy after acute coronary syndromes. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC, Siontis GCM, Piccolo R, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Ezetimibe therapy: mechanism of action and clinical update. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Stroes ES, Thompson PD, Corsini A, et al. High-Intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Patients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.Ĭannon CP, Braunwald E, McCabe CH, et al. During follow-up, the proportion of patients maintaining their initial lipid-lowering therapy was significantly higher in the moderate-intensity statins plus ezetimibe group than in the high-intensity statins group. The multivariable-adjusted HR for a composite of cardiovascular mortality, hospitalization for MI, or hospitalization for stroke was 1.05 (95% CI 0.74–1.47 p = 0.80). The fully adjusted hazard ratio for the primary outcome was 1.11 (95% confidence interval 0.86–1.42 p = 0.43). person-years in the moderate-intensity stains plus ezetimibe and the high-intensity statins group, respectively. ResultsĪt 12 months, the incidence rates of the primary outcome were 138.0 vs. The primary outcome was a composite of cardiovascular mortality, hospitalization for myocardial infarction (MI), hospitalization for stroke, or revascularization. Study participants ( n = 20,070) underwent percutaneous coronary intervention or coronary artery bypass graft surgery between January 1, 2015, and December 31, 2016, and received moderate-intensity statins (atorvastatin 10–20 mg or rosuvastatin 5–10 mg) plus ezetimibe ( n = 922) or high-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20 mg n = 19,148). Population-based cohort study using nationwide medical insurance data from Korea. high-intensity statins after a coronary revascularization procedure using data from a large cohort study. We compared the risk of adverse cardiovascular events in patients receiving moderate-intensity statins plus ezetimibe vs. Whether moderate-intensity statins plus ezetimibe could be an alternative to high-intensity statins in patients with atherosclerotic cardiovascular disease is unclear.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |